Cargando…

Why is immunotherapy for glioblastoma “Lag”-ging

Detalles Bibliográficos
Autores principales:	Mathios, Dimitrios, Lim, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383819/ https://www.ncbi.nlm.nih.gov/pubmed/30815223 http://dx.doi.org/10.18632/oncotarget.26648

Ejemplares similares

Rumms, da ging die Schöpfung los
por: Lindinger, Manfred
Publicado: (2007)

PHARMAMACGNOSTICAL EVALUATION OF IONLDIUM SUFFRLITLCOSAM GING (FAMILY: VIOLACEAE)
por: Boominathan, R., et al.
Publicado: (2005)

Microleakage of Posterior Composite Restorations with Fiber Inserts Using two Adhesives after ging
por: Sharafeddin, F, et al.
Publicado: (2013)

Optimizing the delivery of chemotherapy in the setting of immunotherapy in a preclinical glioblastoma model
por: Mathios, Dimitrios, et al.
Publicado: (2015)

Commentary: Why automation lags
por: Arndt, R. W.
Publicado: (1979)

Antinociceptive effect of some extracts from Ajuga chamaecistus Ging. ssp. tomentella (Boiss.) Rech. f. aerial parts
por: Khanavi, Mahnaz, et al.
Publicado: (2014)

Development of an In Vitro Propagation Protocol and a Sequence Characterized Amplified Region (SCAR) Marker of Viola serpens Wall. ex Ging
por: Jha, Shipra Rani, et al.
Publicado: (2020)

Why the Influence of Women on Boards Still Lags
por: Whitler, Kimberly
Publicado: (2018)

Why Are Genes Encoded on the Lagging Strand of the Bacterial Genome?
por: Chen, Xiaoshu, et al.
Publicado: (2013)

Prizes and Heroes: Lagging and leading indicators
por: Jeang, Kuan-Teh
Publicado: (2010)

Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
por: Nicholas, Sarah, et al.
Publicado: (2013)

Nephrology Lagging Behind in Machine Learning Utilization
por: Cassol, Clarissa, et al.
Publicado: (2021)

LAG3 and its emerging role in cancer immunotherapy
por: Wang, Miao, et al.
Publicado: (2021)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Does chronic jet lag increase risk of cancer?
por: Khan, Suliman, et al.
Publicado: (2021)

Why does the X chromosome lag behind autosomes in GWAS findings?
por: Gorlov, Ivan P., et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Why Cancer & Metabolism? Why now?
por: Van Dang, Chi, et al.
Publicado: (2013)

An Introduction to the Supplemental Issue on Why Does Health in the US Continue to Lag Behind
por: Mehta, Neil K, et al.
Publicado: (2022)

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
por: Cheung, Chun Chau Lawrence, et al.
Publicado: (2023)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

Why Not?
Publicado: (1965)

Why Is It?
Publicado: (1880)

Why Not
Publicado: (1882)

Why Not?
Publicado: (1867)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
por: Long, Long, et al.
Publicado: (2018)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Immunotherapy Resistance in Glioblastoma
por: Wang, Elaina J., et al.
Publicado: (2021)

Why Have Detection, Understanding and Management of Kidney Hypoxic Injury Lagged behind Those for the Heart?
por: Abassi, Zaid, et al.
Publicado: (2019)

Why there are so many submission, why the rush to publish?
por: Shyam, Ashok
Publicado: (2018)

Advances in molecular biomarkers and liquid biopsy in gliomas
por: Mathios, Dimitrios, et al.
Publicado: (2022)

Focus on better care and ethics: Are medical ethics lagging behind the development of new medical technologies?
por: Einav, Sharon, et al.
Publicado: (2020)

Why Nutrients?
por: Howe, Peter
Publicado: (2009)

Why Cancer?
por: Haycox, Alan
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gusj357jkkmicai8n8v5e577u3